ASCEND-ing results: acalabrutinib is well-tolerated and highly effective in R/R CLL
EHA 2019 program: insights from the Chair of the Scientific Program Committee
Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?
Long-term follow-up after SCRI-CAR19v1 in R/R ALL patients who proceeded to transplant
Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL
PAUSE: perioperative management of AF patients receiving direct oral anticoagulants